BiologicalDrug
CA-4948 clinical trials
Also written CA-4948, AU 4948 and Emavusertib.
- studies test it
- 7
- open now
- 4
- in phase 3
- 0
- first study started
- 2022
Keep track of what changes. Save the CA-4948 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
7 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 6
National Cancer Institute (NCI) (4) · Curis, Inc. (1) · Mayo Clinic (1) · University of Leipzig (1)
Often tested with
Tested in the same studies.
Pembrolizumab (2) · Azacitidine (1) · Busulfan (1) · Cytarabine (1) · Daunorubicin (1) · Decitabine and cedazuridine drug combination (1) · Enasidenib (1) · Epoetin Alfa (1)
Studies
Open first, then newest update. How each study uses CA-4948 is read from its arms, and is right about nine times in ten.
Testing it · 7
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Emavusertib
- Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior ImmunotherapyRecruitingPhase 1National Cancer Institute (NCI)NCT06439836Written as Emavusertib
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal CancerRecruitingPhase 1National Cancer Institute (NCI)NCT06696768Written as Emavusertib
- A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesRecruitingPhase 2Curis, Inc.NCT07271667Written as Emavusertib
- CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain MetastasesSuspendedPhase 1/2Mayo ClinicNCT05669352Written as Emavusertib
- CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic CancerSuspendedPhase 1National Cancer Institute (NCI)NCT05685602Written as Emavusertib
- Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948TerminatedPhase 2University of LeipzigNCT05178342Written as CA-4948
Given in every arm · 4 — CA-4948 is usual care beside what is tested
- CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)RecruitingPhase 1/2Curis, Inc.NCT03328078Written as Emavusertib
- A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT07463820Written as Emavusertib
- CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal CancerRecruitingPhase 1Washington University School of MedicineNCT05187182Written as CA-4948
- Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)SuspendedPhase 1/2Curis, Inc.NCT04278768Written as Emavusertib
Codes
What other systems call CA-4948 · ClinicalTrials.gg INT002036
- MeSH (NLM) C000729138CA-4948One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000729138 | CA-4948 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.